Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nanobiotix S.A. ADR (NBTX)

Nanobiotix S.A. ADR (NBTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Nanobiotix Updates Voting Rights and Share Capital Details

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nanobiotix...

NBTX : 21.29 (-0.42%)
This Stock Is Up 440% in a Year. Is It an Undiscovered Star or a Flash in the Pan?

Nanobiotix (NBTX) is a clinical-stage nanomedicine company showing exceptional price momentum and technical strength. Shares are trading at new all-time highs. NBTX has surged 440% over the past year....

NBTX : 21.29 (-0.42%)
Stifel Nicolaus Remains a Buy on Nanobiotix (0QAV)

Stifel Nicolaus analyst Clémence Thiers maintained a Buy rating on Nanobiotix today and set a price target of €25.00. The company’s shares opened today at €18.10.Elevate Your Investing Strategy:...

NBTX : 21.29 (-0.42%)
Jefferies Reaffirms Their Buy Rating on Nanobiotix (0QAV)

Jefferies analyst Lucy Codrington maintained a Buy rating on Nanobiotix today and set a price target of €21.00. The company’s shares opened today at €17.06.Elevate Your Investing Strategy: Take advantage...

NBTX : 21.29 (-0.42%)
Nanobiotix SA ADR Reports Revenue Surge Amid Strategic Advances

Nanobiotix Sa ADR ( (NBTX) ) has released its Q2 earnings. Here is a breakdown of the information Nanobiotix Sa ADR presented to its investors.Elevate Your Investing Strategy: Take advantage of TipRanks...

NBTX : 21.29 (-0.42%)
Nanobiotix Reports Promising Phase 1 Results for Esophageal Cancer Treatment

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nanobiotix...

NBTX : 21.29 (-0.42%)
Nanobiotix: Voting Rights and Shares Capital of the Company

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 21.29 (-0.42%)
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022

Regulatory News:

NBTX : 21.29 (-0.42%)
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022

Regulatory News:

NBTX : 21.29 (-0.42%)
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Regulatory News:

NBTX : 21.29 (-0.42%)

Barchart Exclusives

HSBC Says These 2 AI Stocks Are Likely to Be Earnings Winners. Should You Buy Them Now?
Beaten-down large-cap stocks such as Salesforce and Oracle have significant upside potential given their estimated growth rates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar